Influence of capsule size on the in vitro activity of antifungal agents against clinical Cryptococcus neoformans var. grubii strains

References

1. Bahn Y. S., Cox G. M., Perfect J. R., Heitman J. 2005; Carbonic anhydrase and CO₂ sensing during Cryptococcus neoformans growth, differentiation, and virulence. Curr Biol 15:2013–2020 [View Article][PubMed]
   [Google Scholar]
2. Barreto de Oliveira M. T., Boekhout T., Theelen B., Hagen F., Baroni F. A., Lazera M. S., Lengeler K. B., Heitman J., Rivera I. N., Paula C. R. 2004; Cryptococcus neoformans shows a remarkable genotypic diversity in Brazil. J Clin Microbiol 42:1356–1359 [View Article][PubMed]
   [Google Scholar]
3. Bose I., Reese A. J., Ory J. J., Janbon G., Doering T. L. 2003; A yeast under cover: the capsule of Cryptococcus neoformans. Eukaryot Cell 2:655–663 [View Article][PubMed]
   [Google Scholar]
4. Cherniak R., Morris L. C., Belay T., Spitzer E. D., Casadevall A. 1995; Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect Immun 63:1899–1905[PubMed]
   [Google Scholar]
5. Chowdhary A., Randhawa H. S., Sundar G., Kathuria S., Prakash A., Khan Z., Sun S., Xu J. 2011; In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India. J Med Microbiol 60:961–967 [View Article][PubMed]
   [Google Scholar]
6. CLSI 2008 Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard. Document M27-A3 Wayne, PA: Clinical Laboratory Standards Institute;
   [Google Scholar]
7. D’Souza C. A., Hagen F., Boekhout T., Cox G. M., Heitman J. 2004; Investigation of the basis of virulence in serotype A strains of Cryptococcus neoformans from apparently immunocompetent individuals. Curr Genet 46:92–102 [View Article][PubMed]
   [Google Scholar]
8. Dannaoui E., Abdul M., Arpin M., Michel-Nguyen A., Piens M. A., Favel A., Lortholary O., Dromer F.French Cryptococcosis Study Group 2006; Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother 50:2464–2470 [View Article][PubMed]
   [Google Scholar]
9. Frases S., Pontes B., Nimrichter L., Rodrigues M. L., Viana N. B., Casadevall A. 2009; The elastic properties of the Cryptococcus neoformans capsule. Biophys J 97:937–945 [View Article][PubMed]
   [Google Scholar]
10. Granger D. L., Perfect J. R., Durack D. T. 1985; Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J Clin Invest 76:508–516 [View Article][PubMed]
    [Google Scholar]
11. Janbon G., Himmelreich U., Moyrand F., Improvisi L., Dromer F. 2001; Cas1p is a membrane protein necessary for the O-acetylation of the Cryptococcus neoformans capsular polysaccharide. Mol Microbiol 42:453–467 [View Article][PubMed]
    [Google Scholar]
12. Liu D., Coloe S., Baird R., Pederson J. 2000; Rapid mini-preparation of fungal DNA for PCR. J Clin Microbiol 38:471[PubMed]
    [Google Scholar]
13. Nguyen M. H., Husain S., Clancy C. J., Peacock J. E., Hung C. C., Kontoyiannis D. P., Morris A. J., Heath C. H., Wagener M., Yu V. L. 2010; Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. J Infect 61:419–426 [View Article][PubMed]
    [Google Scholar]
14. Osuna A., Carragoso A., Lemos A., Mocho M. L., Gaspar O. 2008; [Cryptococcosis]. Acta Med Port 21:307–313 (in Portuguese) [PubMed]
    [Google Scholar]
15. Perfect J. R., Dismukes W. E., Dromer F., Goldman D. L., Graybill J. R., Hamill R. J., Harrison T. S., Larsen R. A., Lortholary O. other authors 2010; Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 50:291–322 [View Article][PubMed]
    [Google Scholar]
16. Rivera J., Feldmesser M., Cammer M., Casadevall A. 1998; Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection. Infect Immun 66:5027–5030[PubMed]
    [Google Scholar]
17. Torres H. A., Prieto V. G., Raad I. I., Kontoyiannis D. P. 2005; Proven pulmonary cryptococcosis due to capsule-deficient Cryptococcus neoformans does not differ clinically from proven pulmonary cryptococcosis due to capsule-intact Cr. neoformans. Mycoses 48:21–24 [View Article][PubMed]
    [Google Scholar]
18. van Duin D., Cleare W., Zaragoza O., Casadevall A., Nosanchuk J. D. 2004; Effects of voriconazole on Cryptococcus neoformans. Antimicrob Agents Chemother 48:2014–2020 [View Article][PubMed]
    [Google Scholar]
19. Warn P. A., Sharp A., Guinea J., Denning D. W. 2004; Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida. J Antimicrob Chemother 53:743–749 [View Article][PubMed]
    [Google Scholar]
20. Zaragoza O., Fries B. C., Casadevall A. 2003; Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO₂. Infect Immun 71:6155–6164 [View Article][PubMed]
    [Google Scholar]
21. Zaragoza O., Mihu C., Casadevall A., Nosanchuk J. D. 2005; Effect of amphotericin B on capsule and cell size in Cryptococcus neoformans during murine infection. Antimicrob Agents Chemother 49:4358–4361 [View Article][PubMed]
    [Google Scholar]
22. Zaragoza O., Rodrigues M. L., De Jesus M., Frases S., Dadachova E., Casadevall A. 2009; The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol 68:133–216 [View Article][PubMed]
    [Google Scholar]